Baxter Bros Inc. Reduces Stake in Johnson & Johnson (NYSE:JNJ)

Baxter Bros Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,624 shares of the company's stock after selling 2,419 shares during the quarter. Baxter Bros Inc.'s holdings in Johnson & Johnson were worth $7,032,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Bay Capital Advisors LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $220,000. Potentia Wealth purchased a new stake in Johnson & Johnson during the fourth quarter valued at approximately $724,000. PKS Advisory Services LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $436,000. Syverson Strege & Co grew its holdings in Johnson & Johnson by 4.9% in the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after purchasing an additional 65 shares during the last quarter. Finally, First American Trust FSB lifted its holdings in shares of Johnson & Johnson by 45.3% during the 4th quarter. First American Trust FSB now owns 6,915 shares of the company's stock valued at $1,000,000 after purchasing an additional 2,155 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $2.15 on Tuesday, hitting $161.14. The company's stock had a trading volume of 7,455,754 shares, compared to its average volume of 7,086,516. The company has a market capitalization of $388.32 billion, a price-to-earnings ratio of 24.23, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The firm has a fifty day moving average price of $157.70 and a 200-day moving average price of $156.14. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.

Remove Ads

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analysts' expectations of $22.44 billion. During the same period in the previous year, the business earned $2.29 earnings per share. The business's revenue was up 5.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.08%. Johnson & Johnson's dividend payout ratio is currently 74.59%.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several research analyst reports. Leerink Partners dropped their target price on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada restated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Bank of America boosted their price objective on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a "neutral" rating in a report on Wednesday, March 5th. Finally, Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.